$1.96
Value $185M
CGEN and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$1.96
Value $185M
$272.70
Value $657B
Compugen (CGEN) has a market value of $185M and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, CGEN moved +23.3% and JNJ +39.7%. The P/E is 5.2 for CGEN and 40.8 for JNJ. Dividend yield: CGEN none, JNJ 1.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CGEN$185M
JNJ$657B
JNJ is 3,546 times CGEN
Revenue, 12 months
CGEN$73M
JNJ$99.3B
JNJ is 1,365 times CGEN
Net income, 12 months
CGEN$35M
JNJ$16.1B
JNJ is 455 times CGEN
Operating margin
CGEN43.1%
JNJ–
ROIC
CGEN24.1%
JNJ12.4%
11.7 points apart
P/E
CGEN5.2
JNJ40.8
JNJ is 7.8 times CGEN
Dividend yield
CGEN0.0%
JNJ1.9%
1.9 points apart
5-year return
CGEN-60.2%
JNJ+92.0%
152.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CGEN-60.2%
JNJ+92.0%
| Period | CGENWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +23.3%Price +23.3% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | +221.3%+47.6% a yearPrice +221.3% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | -60.2%-16.8% a yearPrice -60.2% | +92.0%+13.9% a yearPrice +67.0% |
| 10 years since November 18, 2016 | -69.4%-11.2% a yearPrice -69.4% | +208.0%+11.9% a yearPrice +136.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CGENCompugenJNJJohnson & Johnson
| Price | $1.96 | $272.70 |
|---|---|---|
| Market value | $185M | $657B |
| Enterprise value (EV) | $85M | $685B |
| P/E | 5.2 | 40.8 |
| P/E, 5-year median | – | 21.9 |
| P/B | 1.8 | 8.1 |
| EV/EBIT | 2.7 | 38.6 |
| Free cash flow yield | 16.9% | 3.1% |
| Revenue, 12 months | $73M | $99.3B |
|---|---|---|
| Net income, 12 months | $35M | $16.1B |
| Free cash flow, 12 months | $31M | $20.6B |
| Earnings per share, 12 months | $0.38 | $6.59 |
| Revenue growth, year on year | 161.1% | 6.1% |
| Revenue growth a year, past | +105.2%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 87.3% | 67.6% |
|---|---|---|
| Operating margin | 43.1% | – |
| Net margin | 48.6% | 16.2% |
| ROIC | 24.1% | 12.4% |
| ROE | 34.4% | 19.7% |
| Cash | $100M | $17.2B |
|---|---|---|
| Total debt | $3.0M | $44.7B |
| Net debt / EBITDA | -3.1 | 1.1 |
| Interest cover | 1,118.8× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 3,546.1 times Compugen ($185M), at today's prices.
Since November 18, 2016, CGEN's price moved -69.4% and JNJ's +136.4%. With dividends: CGEN -69.4% (-11.2% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Compugen and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 5.2 for CGEN and 40.8 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 48.6% for Compugen and 16.2% for Johnson & Johnson, and the operating margin 43.1% and –. Revenue was $73M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.